Allogeneic Mesenchymal Stem Cell Therapies for Crohn’s Disease

February 1, 2017 | Technology Forecasts


Note: The following ratings and comments reflect the opinions and consensus of an expert panel convened by ECRI Institute to review information on this topic.

Anticipated Utilization: 2(Expected to be used by 20% to 40% of eligible patients)

If approved for marketing by the U.S. Food and Drug Administration (FDA), mesenchymal stem cell (MSC) therapies for treating Crohn's disease (CD) might be adopted among the 240,000 patients who develop fistulas and 48,000 to 120,000 people whose conditions are refractory to other forms of CD treatment and have no other options. Overall adoption of allogeneic MSC-based treatments will largely depend on pending information regarding the safety, efficacy, costs, and reimbursement climate.

Estimated Adoption Status: 1 (Early...

Access Full Content

Contact us today at 610.825.6000.